Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + Amlodipine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome, Hypertension
Trial Timeline
Oct 1, 2008 → May 1, 2011
NCT ID
NCT00891267About Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + Amlodipine
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + Amlodipine is a phase 3 stage product being developed by Daiichi Sankyo for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00891267. Target conditions include Metabolic Syndrome, Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00891267 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Syndrome